StreetInsider.com News Articles

Stifel Starts Candel Therapeutics Inc. (CADL) at Buy

Mon, 13 Jul 2026 02:13:19 -0400

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $22.00.

The analyst comments: “Aglatimagene is a differentiated/versatile, locally-administered viral immunotherapy with a dual mechanismof-action (directly cytotoxic and yielding systemic immune activation) which has been clinically-validated in multiple solid tumor settings. We believe registrational P3 PrTK03 trial data clearly establishes the superiority of aglatimagene (+valacyclovir) vs. placebo on a backbone of standard-of-care radiotherapy (± short-term ADT) in intermediate-risk localized prostate cancer (LPCa) patients, and remain confident a planned YE26 BLA submission will yield a 2H27 regulatory approval and commercial launch

Stifel Starts Candel Therapeutics Inc. (CADL) at Buy

Mon, 13 Jul 2026 02:13:19 -0400

Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics Inc. (NASDAQ: CADL) with a Buy rating and a price target of $22.00.

Form 4 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747673.html

Form 4 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26747673.html

Form 3 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747657.html

Form 3 Candel Therapeutics, For: Jul 06 Filed by: Sims Mark E.

Wed, 08 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260708/26747657.html

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 16:05:00 -0400

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026, the Compensation Committee of Candel’s Board of Directors granted Mark Sims, in connection with his employment as the Chief Commercial Officer of Candel, stock options to purchase an aggregate of 285,000 shares of the Company’s common stock, with a per share exercise price of $10.03, which is equal to the closing price of the Company’s common

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Wed, 08 Jul 2026 16:05:00 -0400

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Barone Francesca

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721055.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Barone Francesca

Wed, 01 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260701/26721055.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Tyagarajan Seshu

Wed, 01 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26721042.html

Form 4 Candel Therapeutics, For: Jun 29 Filed by: Tyagarajan Seshu

Wed, 01 Jul 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260701/26721042.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: PAPA JOSEPH C

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721009.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: PAPA JOSEPH C

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721009.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Manning Paul B

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721022.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Manning Paul B

Wed, 01 Jul 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260701/26721022.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Loggia Nicoletta

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26720996.html

Form 4 Candel Therapeutics, For: Jun 30 Filed by: Loggia Nicoletta

Wed, 01 Jul 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260701/26720996.html

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:05:00 -0400

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on June 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 25,000 shares of the Company’s common stock, with a per share exercise price of $10.30.

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 01 Jul 2026 16:05:00 -0400

The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest

Candel Therapeutics launches phase 3 lung cancer trial for CAN-2409

Tue, 30 Jun 2026 08:05:34 -0400

Candel Therapeutics, Inc. (Nasdaq: CADL) has initiated a global pivotal phase 3 clinical trial, called AURORA, evaluating its investigational therapy aglatimagene besadenovec (CAN-2409) in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed despite prior treatment with pembrolizumab and platinum-based chemotherapy.

The randomized, open-label trial will compare aglatimagene plus valacyclovir in combination with continued pembrolizumab against standard-of-care docetaxel chemotherapy. Patients will be enrolled in a 1:1 ratio across approximately 150 sites worldwide, with the first site now open for enrollment. The primary endpoint is overall survival, with secondary endpoints including safety and quality-of-life assessments.

Candel has engaged Parexel

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response

Tue, 30 Jun 2026 08:05:00 -0400

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior pembrolizumab and platinum chemotherapy
Global pivotal phase 3 trial expected to enroll patients in 1:1 randomization across more than 150 sites; first site now open for enrollment
Primary endpoint is overall survival
Candel has engaged Parexel International to support execution of this global pivotal trial

NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq:

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response

Tue, 30 Jun 2026 08:05:00 -0400

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior pembrolizumab and platinum chemotherapy
Global pivotal phase 3 trial expected to enroll patients in 1:1 randomization across more than 150 sites; first site now open for enrollment
Primary endpoint is overall survival
Candel has engaged Parexel International to support execution of this global pivotal trial

NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq:

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 29 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260629/26707158.html

Form 144 Candel Therapeutics, Filed by: Tyagarajan Seshu

Mon, 29 Jun 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260629/26707158.html